CROI 2018 Abstract eBook

Abstract eBook

Keyword Index

Subtypes 540, 1001 Superinfection 288, 947 Superspreading 336 Surveillance 644, 907, 970, 977, 1019, 1134 Surveillance data 529, 717, 779, 907 Survival 624, 714, 894 Sustained virologic response 608, 609 Swaziland 986, 1143 Switching regimen 22, 346, 500, 501, 504 Symptoms 999, 1000 Synbiotic 275 Syphilis 563, 564, 627, 796, 798, 833, 918, 977, 978, 979 Syringe services program 967, 972, 1158 Systemic 942 Systems biology 117, 233LB Systems serology 228, 300, 301, 312 T cell 225, 285, 391, 392, 743, 749 • Activation 252, 275, 859 • Exhaustion 216, 239, 738, 859 • Immunity 67 • Subsets 239, 346, 868 T follicular helper cells 15, 225, 234, 248, 326, 327, 341, 384 TAF 28LB, 532, 560 Talaromyces marneffei 794 Talaromycosis 794 TAMs 560 Tapasin 206 Targeted Community Outreach Events 883 TasP 581, 1050, 1143 TCF-1 277 TCR cloning 276 Telomere length 758, 760 Temporal trends 228 TEMRA 743 Tenofovir 1060LB, 25, 28LB, 464, 474, 538, 617, 637, 720, 808 Tenofovir alafenamide 473, 478, 500, 504, 506, 560, 618, 673, 677LB, 724, 732, 80, 843, 844 Tenofovir disoproxil fumarate 1059LB, 131, 477, 504, 619,

TLR9 agonist 259, 315 TMAO 708 Togo 1069 Tonsils 326 Total HIV-1 DNA 69LB, 864 Trajectory 968 Transactional Sex 921, 969 Transcription 115, 320 Transcription mediated amplification 571 Transcriptional profile 326, 361 Transcriptionally active proviruses 158 Transcriptome 214, 299, 329, 402

VACS 761, 800 VACS index 407, 761 Vaginal film 1063 Vaginal ring 141, 1057 Vaginal transmission 562 Vascular disease 413, 435, 857 Vietnam 516 Viral

• Blips 990, 1124 • Control 198, 227 • Decay 365 • Diversity 628 • Entry 448 • Evolution 535, 948 • Kinetics 173 • Load 423, 516, 566, 570, 579, 862, 893, 953, 956, 968, 998, 1128, 1130, 1142, 1144 • Load monitoring 571, 989, 990, 1141 • Load suppression 91, 851, 1129 • Rebound 231, 308, 337 • Replication 180, 237, 381, 621 • Reservoir 136, 248, 399, 443, 864 • Reservoir clearance 352 • Suppression 1044, 1052, 1078, 1083, 1107, 1109, 1111LB, 1120, 1121, 1126, 1131, 1132, 1136, 1145, 24, 515, 519, 526, 550, 621, 753, 763, 77, 813, 815, 821, 848, 852, 854, 888, 893, 904, 908, 934, 95, 955, 96, 975 • Trajectory 1136 Virologic failure 514, 517, 530, 537, 812, 813, 1118 Virologic response 510, 558, 861 Visceral Fat 685, 734 Visit intervals 817 Vitamin D 406, 719, 836, 859 Vitamin D binding protein 406 White matter abnormalities 433, 435 Wirelessly Observed Therapy (WOT) 782 WNT signaling 220 Women 138, 268, 337, 420, 500, 678, 694, 695, 811, 812, 917, 921, 933, 1043, 1048, 1051, 1063, 1069, 1072, 1073 Women who exchange sex 920, 921 Women’s health 461 Xpert HIV-1 viral load assay 1142 Xpert MTB/RIF 31 Young adults 846, 926, 1094 Young black men 1126 Young black MSM 915, 1008 Young men 906 Young people 848, 1077 Young women 271, 522, 551, 924, 992, 1049 Zambia 537, 614, 830, 831, 900, 918, 996, 1105, 1119 VMMC 1065 Vpr 190, 247 VRC01 319LB VRC07-523LS 1061

Transgender 42, 204, 979, 994, 1009, 1017, 1040, 1044, 1045 Transmission 1098, 195, 267, 40, 778, 947, 948, 949, 963, 976LB • Cluster 40, 581, 938, 949, 954, 955, 956, 959 • Network 42, 43, 523, 949, 950, 951, 954, 956, 957 • Pairs 195, 944 • Risk 904, 957, 966, 976LB Transmitted drug resistance 523, 525, 527 Transmitted founder virus 192, 377

Treated HIV infection 122 Treatment 128, 605, 780, 806 • As prevention 87, 519 • Experienced 499, 502, 509, 510, 561 • Failure 127, 539, 540 • Initiators 601, 776, 1083, 1106 • Interruption 137, 335, 337, 338, 364, 373 • Naïve 492, 532 • Outcomes 780, 1028 • Strategies 93 Trends 654, 933 Treponema pallidum 798 TRIAL 602

TRIM-5 369 TRIM21 200 Trispecific antibody 113LB Tropism 553 Troponin T 699 TSPO imaging 441LB Tuberculin skin test 766, 767 Tuberculosis 1114, 28LB, 31, 33, 34, 37LB, 39LB, 455, 457, 714, 766, 767, 769, 770, 772, 777, 778, 782, 838, 839 • And HIV 1117LB, 29LB, 455, 766, 767, 768, 771, 774, 776, 837, 845, 899 • Diagnosis 1117LB, 38LB, 767, 771, 772 • Prevalence 766, 839 • Prophylaxis 142LB, 32, 839 Turnaround time 989, 990 Type 2 diabetes mellitus 741 Uganda 226, 405, 407, 540, 721, 771, 814, 872, 1001, 1122 Ukraine 929, 961 Ultradeep sequencing 534 Ultrasensitive viral load 393, 518, 575

723, 724, 725, 831 Tesamorelin 736 Test and start 854 Test and treat 979, 1143

Testing 146, 598, 931, 962, 987 Testing coverage 825, 987, 988 Testis 371 Tetanus toxoid vaccine 1064 Text message 818 Tfh 284 TFV-DP 464

Keyword Index

Th1 cells 774 Th17 20, 243 Th17 cells 17, 240, 682

Thailand 626, 719 Thrombosis 674 Thymus 759

Undiagnosed HIV 988, 994 Urine based assay 38LB, 729 V1/V2 loop 292 V2-loop 184, 319LB

Zidovudine 538 Zimbawe 1152 Zinc therapy 693 Zoledronic acid 723 Zonulin 867 Zoster Vaccine 800

TIGIT 316 TIM-3 201 Time and motion 1076 Time to ART initiation 1105, 1106, 1109 Time to viral rebound 137, 359 Tipping points 1155 Tissue factor 678 TLR 321

V3-loop 292 VAC-3S 310 Vaccination 660, 663, 827, 869 Vaccine 293, 1153, 16LB, 294, 300, 309, 310, 870 • Efficacy prediction 304 • Interference 871 • Response 117, 213, 305, 308, 625, 871

TLR-4 281 TLR7 73LB

CROI 2018 483